Twice-yearly injectable lenacapavir, an HIV-prevention drug, reduces risk by 96%
Gilead researchers say lenacapavir “has the potential to be one of the most impactful interventions” in the battle against HIV.
September 13, 2024
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Gilead researchers say lenacapavir “has the potential to be one of the most impactful interventions” in the battle against HIV.
LGBTQ+ activists in the U.K. are criticizing this restriction on care for transgender youth.
In an exclusive clip from Ending Disease, Andrew shares how he hopes his participation in a clinical trial could change the world.
